Gilead Entered into a 12-Year Partnership with Assembly Biosciences to Develop Novel Antiviral Therapies
Shots:
- Assembly Bio will receive $100M i.e., $84.8M up front & $15.2M in equity investment giving Gilead a 19.9% stake in the company, ~$330M per program in milestones along with royalties if Gilead exercises its opt-in right to current or future program & will be eligible to receive 3 separate $75M collaboration extension fees
- Assembly Bio gets the right to opt-in for profits & cost-sharing in the US if Gilead exercises its option for an Assembly Bio program & gets an option to co-promote those products in the US for new programs. Gilead will control the discovery, research, development & commercialization of the optioned program & obtain exclusive rights to all of Assembly Bio’s current & future programs
- The collaboration combines Gilead’s mission for transformative therapies targeting serious viral diseases & Assembly Bio’s expertise to advance treatments for herpesviruses, HBV, HDV
Ref: Assembly | Image: Gilead
Related News:- Gilead Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Magrolimab for Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
